EQS-News: Gerresheimer successfully completes acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group
|
EQS-News: Gerresheimer AG
/ Key word(s): Mergers & Acquisitions
Gerresheimer successfully completes acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group
Düsseldorf, December 11, 2024 - Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and cosmetics industries, has successfully completed the acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group announced in May 2024. The closing was preceded by the fulfillment of customary closing conditions. Bormioli Pharma has a portfolio of pharmaceutical primary packaging made of glass and plastic as well as closure solutions, accessories and dosing systems that is complementary to Gerresheimer. With this acquisition, Gerresheimer strengthens its European footprint with additional production sites and underpins its market position as a leading full-service provider and global partner for the pharma and biotech industries. Gerresheimer expects the acquisition to be accretive to the Group's Adj. EBITDA margin and Adj. EPS from the first year onwards through synergies. On February 26, 2025, Gerresheimer will publish a new guidance for the combined company together with the results for the financial year 2024. "Following the successful completion of the acquisition, we can now focus on the integration of Bormioli Pharma into the Gerresheimer Group," explains Dietmar Siemssen, CEO of Gerresheimer AG. "We are convinced that our customers will benefit from the expansion of the product portfolio and new, integrated systems and solutions." Complementary, attractive product portfolio In 2023, Bormioli Pharma generated sales of around EUR 371 million and an Adj. EBITDA margin of around 22%. The company manufactures pharmaceutical primary packaging made of glass and plastic as well as closure solutions, accessories and dosing systems. In the plastics segment, Bormioli Pharma is one of the leading suppliers of pharmaceutical plastic systems and solutions. In the glass segment, Bormioli Pharma has an attractive portfolio for parenteral and other pharmaceutical primary packaging. Strategic reset of Moulded Glass business The acquisition creates a new, strong Moulded Glass unit with a diversified product portfolio for the pharmaceutical, cosmetics, food and beverage industries. This globally active unit offers new options for a strategic reset for the best growth prospects and competitiveness, which will be evaluated in the coming months. New guidance for combined company in February 2025 Bormioli Pharma will become part of the Gerresheimer Group and will be fully consolidated retroactively as of December 1, 2024, the start of Gerresheimer's new financial year 2025. Therefore, on February 26, 2025, together with the results for the financial year 2024, Gerresheimer will publish a new guidance for 2025 and a new mid-term guidance for the combined company.
About Bormioli Pharma Established in 1825, Bormioli Pharma is a leading pharma primary packaging manufacturer serving the industry with complete solutions, including glass and plastic bottles, plastic and aluminum closures and accessories. Bormioli Pharma's products are designed and manufactured to drive innovation and deliver effective solutions to the growing challenges of sustainability. Bormioli Pharma has become part of the Gerresheimer Group in December 2024, an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of drug containment solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. Gerresheimer operates over 40 production sites in 16 countries in Europe, America and Asia and currently employs around 13,400 people.
About Gerresheimer
11.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Gerresheimer AG |
| Klaus-Bungert-Str. 4 | |
| 40468 Duesseldorf | |
| Germany | |
| Phone: | +49-(0)211/61 81-00 |
| Fax: | +49-(0)211/61 81-121 |
| E-mail: | gerresheimer.ir@gerresheimer.com |
| Internet: | http://www.gerresheimer.com |
| ISIN: | DE000A0LD6E6 |
| WKN: | A0LD6E |
| Indices: | MDAX (Aktie) |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2048177 |
| End of News | EQS News Service |
|
|
2048177 11.12.2024 CET/CEST
Zur besseren Einschätzung der fundamentalen Entwicklung der jeweiligen Unternehmen bietet boersengefluester.de (BGFL) eine Übersicht mit den wesentlichen Kennzahlen zu Umsatz, Ergebnis, Cashflow und Dividende. Sämtliche Angaben werden manuell in unserer Datenbank erfasst – Quelle sind die jeweiligen Geschäftsberichte. Sofern es sich um Schätzungen für künftige Zahlen handelt, stammen sie durchweg von BGFL.
| Die wichtigsten Finanzdaten auf einen Blick | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Umsatzerlöse1 | 1.367,73 | 1.392,26 | 1.418,79 | 1.498,01 | 1.817,09 | 1.990,49 | 2.060,00 | |
| EBITDA1,2 | 298,60 | 400,01 | 310,14 | 306,31 | 340,87 | 399,42 | 422,00 | |
| EBITDA-Marge3 | 21,83 | 28,73 | 21,86 | 20,45 | 18,76 | 20,07 | 20,49 | |
| EBIT1,4 | 139,46 | 123,76 | 156,46 | 147,44 | 169,31 | 213,39 | 222,00 | |
| EBIT-Marge5 | 10,20 | 8,89 | 11,03 | 9,84 | 9,32 | 10,72 | 10,78 | |
| Jahresüberschuss1 | 131,13 | 82,68 | 89,88 | 87,24 | 102,19 | 120,09 | 124,00 | |
| Netto-Marge6 | 9,59 | 5,94 | 6,34 | 5,82 | 5,62 | 6,03 | 6,02 | |
| Cashflow1,7 | 173,47 | 192,92 | 222,19 | 212,08 | 221,94 | 294,34 | 0,00 | |
| Ergebnis je Aktie8 | 4,11 | 2,57 | 2,82 | 2,67 | 3,06 | 3,48 | 2,56 | |
| Dividende8 | 1,15 | 1,20 | 1,25 | 1,25 | 1,25 | 1,25 | 1,40 | |
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Deloitte
Alle relevanten Bewertungskennzahlen, Termine und sonstige Investor-Informationen zu Ihrer Aktie kompakt zusammengefasst. Gut zu wissen: Sämtliche Daten stammen von boersengefluester.de werden täglich aktualisiert. Damit sind Sie immer auf dem neuen Stand. Kurze Erkärungen zu den Kennzahlen bekommen Sie, wenn Sie mit dem Cursor bzw. der Maus auf das jeweilige Feld gehen.
| INVESTOR-INFORMATIONEN | ||||||
| ©boersengefluester.de | ||||||
| Gerresheimer | ||||||
| WKN | ISIN | Rechtsform | Börsenwert | IPO | Einschätzung | Plus Code |
| A0LD6E | DE000A0LD6E6 | AG | 2.336,63 Mio € | 11.06.2007 | Halten | 9F387QF9+73 |
| KGV 2025e | KGV 10Y-Ø | BGFL-Ratio | Shiller-KGV | KBV | KCV | KUV |
| 16,91 | 23,92 | 0,71 | 20,54 | 1,67 | 7,94 | 1,17 |
|
Dividende '2022 in € |
Dividende '2023 in € |
Dividende '2024e in € |
Div.-Rendite '2024e in % |
| 1,25 | 1,25 | 1,40 | 2,07% |
| Hauptversammlung | Q1-Zahlen | Q2-Zahlen | Q3-Zahlen | Bilanz-PK |
| 05.06.2025 | 11.04.2025 | 10.07.2025 | 10.10.2024 | 26.02.2025 |
| Abstand 60-Tage-Linie | Abstand 200-Tage-Linie | Performance YtD | Kursveränderung 52 Wochen | IPO |
| -12,73% | -27,82% | -28,30% | -28,94% | +69,13% |
Auf dem 2013 von Gereon Kruse gegründeten Finanzportal boersengefluester.de dreht sich alles um deutsche Aktien – mit klarem Schwerpunkt auf Nebenwerte. Neben klassischen redaktionellen Beiträgen sticht die Seite insbesondere durch eine Vielzahl an selbst entwickelten Analysetools hervor. Basis sämtlicher Tools ist eine komplett selbst gepflegte Datenbank für mehr als 650 Aktien. Damit erstellt boersengefluester.de Deutschlands größte Gewinn- und Dividendenprognose.
Kontakt
